Longitudinal changes in laboratory parameters and QTc during isavuconazole therapy in Japanese patients with hematologic malignancies
PLOS One · 29.07.2026 · 21 (7) · e0354816
DOI: 10.1371/journal.pone.0354816 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 29.07.2026. Verfasst von Koichi Ohata und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Gifu University Hospital, Gifu, Japan. Hauptthemen laut MEDLINE: Triazoles, Nitriles, Pyridines, Hematologic Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asahi Kasei Pharma Corporation.
Abstract (Originalsprache)
Background
Isavuconazole (ISCZ) is an azole antifungal with a low risk of QTc prolongation and no requirement for renal dose adjustment. However, real-world data in Asian patients remain limited.
Methods
We retrospectively evaluated 45 patients who received ISCZ between April 2023 and March 2025. Laboratory parameters and QTc values (QTcB/QTcF) were extracted from medical records. Longitudinal changes were assessed using linear mixed-effects models. In patients receiving arsenic trioxide (ATO), QTc trajectories were compared among ATO alone, ATO with ISCZ (ATO-ISCZ), and ATO with other antifungals.
Results
Grade ≥2 elevations in AST and ALT occurred in 11.1% and 13.3% of patients, respectively, and were transient. No significant deterioration in laboratory parameters was observed. In the ATO subgroup, QTc values in the ATO-ISCZ group were lower than those in the ATO group from Day 30, with the largest difference at Day 70 (−45.5 ms for QTcB and −42.3 ms for QTcF; both p < 0.001). The ATO–other antifungals group showed similar trends to the ATO group. No clinically significant cardiac events were observed.
Conclusions
ISCZ showed a favorable safety profile in Japanese patients with hematologic malignancies and may be a safe option during QT-prolonging therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
- Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
- Medical Affairs Department, Asahi Kasei Therapeutics Corporation, Chiyoda-ku, Tokyo, Japan.
- Department of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.
- Center for Nutrition Support and Infection Control, Gifu University Hospital, Gifu, Japan.
ORCID-Profile: Ryo Kobayashi, Yuto Yamada, Mio Wada, Nobuhiko Nakamura, Nobuhiro Kanemura
Förderung
- Asahi Kasei Pharma Corporation
Zitieren
APA
Ohata, K., Kobayashi, R., Watanabe, D., Yamada, Y., Niwa, T., Wada, M., Ohashi, M., Kaneda, Y., Ikoma, Y., Matsumoto, T., Nakamura, N., Nakamura, H., Kanemura, N., Shimizu, M., & Suzuki, A. (2026). Longitudinal changes in laboratory parameters and QTc during isavuconazole therapy in Japanese patients with hematologic malignancies. PLOS One, 21(7), e0354816. https://doi.org/10.1371/journal.pone.0354816
Vancouver
Ohata K, Kobayashi R, Watanabe D, Yamada Y, Niwa T, Wada M, et al. Longitudinal changes in laboratory parameters and QTc during isavuconazole therapy in Japanese patients with hematologic malignancies. PLOS One. 2026;21(7):e0354816. doi:10.1371/journal.pone.0354816
BibTeX
@article{Ohata2026,
author = {Ohata, Koichi and Kobayashi, Ryo and Watanabe, Daichi and Yamada, Yuto and Niwa, Takashi and Wada, Mio and Ohashi, Momoko and Kaneda, Yuto and Ikoma, Yoshikazu and Matsumoto, Takuro and Nakamura, Nobuhiko and Nakamura, Hiroshi and Kanemura, Nobuhiro and Shimizu, Masahito and Suzuki, Akio},
title = {Longitudinal changes in laboratory parameters and QTc during isavuconazole therapy in Japanese patients with hematologic malignancies},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0354816},
doi = {10.1371/journal.pone.0354816}
}
EUVIMED